Schisandra: Traditional Use, Constituents and Evidence

A berry that answers to five flavours

The Chinese name for it , wǔ wèi zǐ , translates as "five-flavour fruit", because the dried berry is said to carry sour, bitter, sweet, pungent and salty all at once. I first came across Schisandra in a battered 1920s herbal that turned up at a Stirling market stall, and the description stopped me cold. Five flavours on one fruit. That's either poetry or a very old attempt at pharmacognosy, and I've been unconvinced it's only poetry ever since.

Schisandra chinensis is a woody vine native to northeastern China, Korea and parts of Russia's Far East. The berry has appeared in Chinese materia medica for roughly two thousand years; the earliest substantial written record is in the Shennong Bencao Jing, a foundational classical text compiled sometime around the first to third century CE. Traditional use encompassed the berry as an astringent, a tonic for the lungs and kidneys, and a substance intended to support vitality across long periods , what classical Chinese medicine classified broadly as a restorative. Russian folk medicine in Siberia and the Russian Far East documented similar long-term tonic use independently, which is part of why Soviet-era researchers took an interest in the 1950s and 60s.

Key constituents: the lignan family

The chemistry of Schisandra is dominated by a group of compounds called dibenzocyclooctadiene lignans. The most studied are schisandrin (also written schizandrin), schisandrin B, schisandrin C, schisandrol A and B, gomisin A, and deoxyschisandrin. These lignans are concentrated mainly in the seed; the pulp carries a different but overlapping profile. The berry also contains organic acids (citric, malic, tartaric), volatile compounds, small amounts of essential oils, and polysaccharides.

Lignans as a class interact with several biological pathways. Preclinical research; almost entirely in cell lines and rodent models, has examined the lignans' behaviour in relation to cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9. This is worth flagging for a reason I'll come back to. The volatile fraction includes some terpene constituents, though in different proportions and character to the terpene profiles you'd encounter in cannabis research.

When you see Schisandra sold as a dietary supplement, the listing may refer to a standardised extract, typically standardised to schisandrin or total lignans. Standardisation matters because dried whole berry, powdered fruit, and a concentrated extract can have substantially different lignan concentrations, which makes comparing traditional use with modern supplementation genuinely difficult.

What the research record looks like; and where it falls short

Honestly, this is the part where anyone writing about traditional botanicals needs to slow down. There is a reasonable body of preclinical research on Schisandra lignans. There is a much thinner body of human clinical trials, and most of the trials that exist are small, used varying doses and extract types, and were published without full blinding protocols.

A 2020 narrative review published via PubMed (Szopa et al.) surveyed the phytochemistry and documented biological activity of Schisandra across multiple studies. The authors noted consistent findings in hepatocyte-model studies around how lignans interacted with liver cell lines, but were explicit that translation to human clinical outcomes couldn't be assumed. That's a fair summary of where the evidence sits across most Schisandra research: interesting preclinical signals, insufficient human data to draw firm conclusions.

The Soviet adaptogen research from the 1960s and 70s, which coined the very term "adaptogen" partly in reference to plants like Schisandra, is worth mentioning historically, but those studies rarely meet current methodological standards. I'd argue that over-citing that literature as clinical evidence is one of the persistent problems in how Schisandra gets written about, and I'd rather just name it plainly.

For anyone interested in pharmacokinetics: lignans from Schisandra show variable oral bioavailability, partly because of interactions with intestinal and hepatic metabolism. First-pass metabolism in the liver significantly affects the circulating levels of some lignans after oral dosing; a factor that also raises questions about whether dried berry preparations and concentrated extracts are directly comparable.

The CYP enzyme question

One area of Schisandra research that warrants specific attention is the documented interaction with cytochrome P450 enzymes. In vitro and some in vivo studies have found that schisandrin B and related compounds can inhibit CYP3A4 and CYP2C9 activity. CYP3A4 is involved in metabolising a very large proportion of pharmaceutical drugs, estimates vary, but it's often cited at roughly 50% of clinically used medicines.

What this means practically: if someone is taking Schisandra alongside other medicines, there is a plausible mechanism for interactions affecting drug concentrations. This is not unique to Schisandra, St John's Wort, grapefruit and several other botanical preparations affect the same enzymes; but it's a reason why people taking prescribed medications should discuss any complementary medicine with their prescriber before use. This isn't a hedge; it's a real biochemical question with real literature behind it.

How Schisandra sits under Australian regulation

In Australia, Schisandra products sold to consumers as complementary medicines fall under the Therapeutic Goods Administration's framework. The TGA maintains the Australian Register of Therapeutic Goods (ARTG), and listed complementary medicines (ARTG "L" products) are assessed for safety and quality but not efficacy before listing. This is a meaningful distinction: a product can carry an ARTG listing without the TGA having evaluated whether it does what the label suggests.

Under the TGA's Permitted Indications framework, complementary medicine sponsors may use pre-approved indications for listed products. Claims must fall within what the TGA permits, they cannot make therapeutic claims of the kind that would require registration (an "R" product), which involves a higher evidentiary bar. A Schisandra listed product cannot legally be promoted to treat, cure or prevent any specific disease without meeting that registered-medicine threshold.

Schisandra itself carries no specific import restriction under Australian border controls (unlike, say, kava, which has had a complex history of import controls under Australian customs regulations for personal use). As a botanical ingredient, it can be legally sold in listed complementary medicine products that meet TGA manufacturing and labelling requirements, including Good Manufacturing Practice standards.

None of this is the same as saying the products are proven to work. It means they've met a baseline safety and quality threshold for listing. Worth keeping those two things distinct.

Traditional context versus modern framing

One thing I keep returning to with Schisandra, and this is true of a lot of traditional botanicals I read about; is how poorly the classical framing maps onto how the plant gets marketed today. In classical Chinese medicine, wǔ wèi zǐ was used as part of multi-herb formulae, dosed according to constitutional patterns, and deployed differently for different presentations. The modern supplement approach of a single standardised extract at a fixed daily dose is a very different thing, and the evidence base for one doesn't automatically transfer to the other.

That's not an argument against studying the plant's constituents, the lignan pharmacology is genuinely interesting, and understanding how schisandrin interacts with hepatic enzymes has real scientific value. But the gap between "this compound does X in a cell line" and "take this capsule for your health" is where a lot of botanical marketing quietly slides, and Schisandra is no exception.

As a phytomedicine subject, it sits in a broadly similar position to a number of other traditional botanicals now finding their way into the contemporary supplement market: a long traditional record, an interesting but preliminary chemistry, and clinical evidence that hasn't yet caught up. Watching that gap either close or fail to close over the next decade of research will be the interesting part.

I killed my third attempt at growing a Schisandra vine last summer, too dry, even with irrigation. The ones doing well in South Australia seem to need a sheltered, humid gully. Nan would have found somewhere for it, I'm sure.

Sources

• Szopa A et al. (2020), "Current knowledge of Schisandra chinensis (Turcz.) Baill. (Chinese magnolia vine) as a medicinal plant species"; NCBI/PubMed
• Listed medicines regulatory framework, Therapeutic Goods Administration (TGA)
• Permitted indications for listed complementary medicines, TGA
• Natural Standard: Schisandra; NCBI Bookshelf

, Naomi Ellison, Botanical & phytomedicine writer